ERBB2 and breast cancer: Another meta-analysis, involving 5390 HR-positive/HER2-positive BC patients from six randomized trials (TEAM, ATAC, BIG 1–98, TEXT, SOFT, and ALTTO), revealed no significant difference between adjuvant treatment with AIs versus tamoxifen (hazard ratio 0.99, 95% CI 0.68–1.44, p = 0.96; I2 =72.9%, p = 0.005).